Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…Abstract Number: 1721 • 2016 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data
Background/Purpose: Psoriatic Arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA)…Abstract Number: 2652 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a lower life expectancy than general population. The impact of RA treatments on global mortality is not…Abstract Number: 252 • 2016 ACR/ARHP Annual Meeting
Cytokine Profiles of Korean Patients with Adult Onset Still’s Disease Treated with Biologic Agents
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Several studies have reported that pro-inflammatory cytokines including interleukin (IL)-1, IL-6,…Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…Abstract Number: 1736 • 2016 ACR/ARHP Annual Meeting
Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study
Background/Purpose: TNF inhibitors (TNFi) are effective treatment in radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA). Nr-axSpA have lower response rate in case of absence…Abstract Number: 2718 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of the M2 Macrophage Markers, CD163 and CD206, Changes Reversely and Soluble CD163 Is Associated with Disease Activity in Spondyloarthritis
Background/Purpose: Spondyloarthritis (SpA) covers a group of interrelated auto-inflammatory disorders where TNFa is a central mediator of disease. T cells and macrophages are abundant in…Abstract Number: 433 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Background/Purpose: Biologicals are a powerful treatment option for moderate to severe immune-mediated inflammatory diseases (IMID). Since biologicals modulate the immune system, the risk for reactivation…Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…Abstract Number: 2005 • 2016 ACR/ARHP Annual Meeting
Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis
Background/Purpose: To evaluate drug-free sustained clinical remission and clinical relapse after induction therapy with golimumab in patients with active peripheral Spondyloarthritis (pSpA) in a very…Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…Abstract Number: 1331 • 2015 ACR/ARHP Annual Meeting
Change in MRI in Patients with Spondyloarthritis Treated with Anti-TNF Agents : Systematic Review of the Literature
Background/Purpose: The follow-up of axial spondyloarthritis (SpA) remains difficult in clinical practice, mainly based on patient-reported outcomes, whereas objective parameters in disease monitoring are often…Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…Abstract Number: 2867 • 2015 ACR/ARHP Annual Meeting
Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study
Background/Purpose: Progression of psoriatic arthritis (PsA) can lead to irreversible joint damage and functional impairment. TNF inhibitors (TNFi’s) have been shown to improve signs and…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 29
- Next Page »